Article Text

Download PDFPDF
EP313 Additional chemotherapy after six cycles in stable disease of cervical cancer
  1. WY Hwang,
  2. JY Kim,
  3. DH Suh,
  4. KD Kim,
  5. JH No and
  6. YB Kim
  1. Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea


Introduction/Background Current treatment guidelines don’t mention how many cycles of chemotherapy are needed for appropriate tumor remission. This study was performed to evaluate the efficacy of additional cycles of chemotherapy in cervical cancer patients with tumor response of stable disease (SD) after six cycles.

Methodology A total of 12 women who showed tumor response of SD with tumor ≥5 mm after six cycles of chemotherapy for the treatment of cervical cancer were reviewed. After excluding two who received radiation therapy, 10 were included in the analysis. Eight received chemotherapy for recurred tumor and two received primary palliative chemotherapy for stage IVB disease.

Recurred tumors which were followed up as target lesions during chemotherapy were located at lung, lymph nodes (common iliac, para-aortic, and supraclavicular), bladder, perihepatic, and retrovesical space. Progression-free survival (PFS) was compared according to the cycle number of chemotherapies (6 vs. 9 cycles).

Results Median age was 50 years (range, 25–78 years). Eight received 6 cycles of chemotherapy. Tumor size on CT scan after six cycles of chemotherapy was 0.8±0.3 cm (mean±SD). Among the rest two undergoing 9 cycles of chemotherapy, one received paclitaxel/cisplatin/bevacizumab as primary palliative therapy and the other received paclitaxel/cisplatin for recurrent disease. The regimen used included paclitaxel/cisplatin with (n=3) or without (n=4) bevacizumab and paclitaxel/carboplatin (n=3). There were 6 patients (60%) who showed disease progression. Median PFS was 18 months (range, 10–106 months). Median PFS was similar between the two groups (19 months for 6 cycles vs. 12 months for 9 cycles; p=0.444). Cycle number (6 vs. 9 cycles) was not an independent factor for longer PFS (p=0.859). Neither were bevacizumab containing regimen, old age, and recurrence.

Conclusion Additional chemotherapy does not seem to benefit patients with cervical cancer who showed SD response after six cycles of platinum-based combination chemotherapy in terms of PFS.

Disclosure Nothing to disclose.

Abstract EP313 Figure 1

Flow chart of patient selection process

Abstract EP313 Table 1

Summary of patient characteristics and management

Adenoca: Adenocarcinoma, TC: Paclitaxel/Carboplatin, TPB: Paclitaxel/Cisplatin/Bevacizumab, TP: Paclitaxel/Cisplatin, SCN: Supraclavicular lymph node, PALN: Paraaortic lymph node, PFS, progression-free survival

Abstract EP313 Table 2

Characteristics of the patients according to Number of cycles of platinum-based chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.